(Q46417627)

English

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

zoledronic acid

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

author name string

Brigitte Mlineritsch

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Gero Luschin-Ebengreuth

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Franz Kainberger

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Helmut Kässmann

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Jutta Claudia Piswanger-Sölkner

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Michael Seifert

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Ferdinand Ploner

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Christian Menzel

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Peter Dubsky

10

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Florian Fitzal

11

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Vesna Bjelic-Radisic

12

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Günther Steger

13

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Richard Greil

14

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Christian Marth

15

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Ernst Kubista

16

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Hellmut Samonigg

17

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Peter Wohlmuth

18

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Martina Mittlböck

19

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Raimund Jakesz

20

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Austrian Breast and Colorectal Cancer Study Group (ABCSG)

21

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

publication date

19 August 2008

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

840-849

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 r

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A new look at the statistical model identification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence that Tamoxifen Preserves Bone Density in Late Postmenopausal Women with Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Important determinants of bone strength: beyond bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mineral density thresholds for pharmacological intervention to prevent fractures

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970204-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(08)70204-3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/18718815

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46417627&oldid=2110432304"